Vetoquinol

Vetoquinol

Develops and markets veterinary medicines

Overview

Vetoquinol is a global animal health company that develops and markets medicines and health products for pets and livestock. Its products are used to treat diseases, prevent illness, and support animal well-being, distributed through a network of subsidiaries and partners in about 24 direct countries with products available in around 100 countries. Core operations include research, development, and commercialisation of veterinary pharmaceuticals and health solutions for both companion and farm animals. What sets Vetoquinol apart is its long family-led history and steady international expansion, including an IPO in 2006 to accelerate growth, which has helped it build a widespread, multi-country presence. The company’s goal is to improve animal health globally by bringing effective veterinary products to markets around the world and expanding access through direct operations and partnerships.

About Vetoquinol

Simplify's Rating
Why Vetoquinol is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Healthcare

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Paris, France

Founded

1933

Get referred to Vetoquinol

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 U.S. sales rose 15.6% constant-currency, showing strong American demand.
  • 2025 EBIT before amortization reached €91.5M and net cash hit €205.8M.
  • Essential Products grew 4.1% in 2025, and management is preparing 2027 launches.

What critics are saying

  • 2025 recalls for FOLLTROPIN in the U.S., UK, and Canada damaged quality credibility.
  • Q1 2026 sales fell 4.3% reported, with €5.2M currency drag hitting U.S. and India.
  • The 2027 launch dependence makes 2026 a transition year if pipeline timing slips.

What makes Vetoquinol unique

  • Vetoquinol’s 2025 Essential Products reached €334.5M, 64% of sales, strengthening mix.
  • It internalized parasiticide manufacturing in 2025, improving control over critical supply.
  • Command Centre ACT extends VetImpress, bundling software, compliance, and revenue management for practices.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$0

Below

Industry Average

Funded Over

1 Rounds

Acquisition funding comparison data is currently unavailable. We're working to provide this information soon!
Acquisition Funding Comparison
Coming Soon

Benefits

Health Insurance

Disability Insurance

Paid Vacation

Commuter Benefits

Wellness Program

Professional Development Budget

Training Programs

Stock Price

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

2%

2 year growth

2%
Yahoo Finance
Apr 28th, 2026
Vetoquinol Q1 2026 sales flat at $141M amid currency headwinds and product simplification

Vetoquinol, a French animal health company, reported first-quarter 2026 sales of €125 million, down 4.3% on a reported basis but flat at constant exchange rates. Excluding currency effects and a product line simplification programme, sales increased 1.2% year-on-year. Exchange rate headwinds reached €5.2 million, primarily affecting the United States and India. The product line simplification programme impacted sales by €1.7 million. Essential products sales totalled €83 million, stable at constant exchange rates, whilst complementary products grew, driven by strong US performance. US sales rose 15.6% at constant exchange rates to €28 million. Companion animal products represented 71% of sales at €93 million, whilst farm animal products totalled €38 million. The company described 2026 as a transition year ahead of new product launches in 2027.

Veterinary Business Development Ltd
Apr 20th, 2026
Vetoquinol launches Command Centre ACT.

Vetoquinol launches Command Centre ACT. The platform creates 'clear accountability' and eases the administrative burden of tracking vaccinations and farm visits. A veterinary pharmaceutical company has launched a dashboard to help ease administrative burdens on farm and mixed practices and drive revenue growth and clinical compliance. Vetoquinol has launched Command Centre ACT, a dashboard extension for its VetImpress data management platform designed for clinical directors and business development staff. The extension is said to draw on practices' data stored within VetImpress or their practice management system to identify revenue opportunities and compliance gaps. Based on analysis using leptospirosis, bovine viral diarrhoea and infectious bovine rhinotracheitis, Vetoquinol estimates that in dairy herds alone, missed vaccination doses, lapsed vaccinations and unvaccinated herds demonstrate an opportunity of around £2,877 annually per farm vet. 'Strategic approach' As well as optimising vaccine scheduling and compliance, Command Centre ACT is said to address regulatory requirements such as Veterinary Medicines Requirements "animals under care" guidelines, automatically flagging farms that are due visits to visually inspect livestock. Vetoquinol product manager Andy Paine said: "The dashboard's name reflects its strategic approach to practice management. "Command Centre ACT enables the user to identify farms requiring attention and assign specific follow-up actions to individual vets through the VetImpress diary and tasks system, creating clear accountability whilst maintaining clinical focus. "We're ultimately selling accountability, but we're striking the right balance between management oversight and clinical autonomy." Work and well being 20 Apr 2026 Small animal 3 Mar 2026

Yahoo Finance
Jan 29th, 2026
Vetoquinol reaches €526M in 2025 sales despite currency headwinds, Essential Products up 4.1%

Vetoquinol, a French veterinary pharmaceutical company, reported annual sales of €526 million for 2025, up 0.2% at constant exchange rates but down 2.5% on a reported basis. The company faced historically high negative currency impacts of €14.8 million and a €9.7 million decline from simplifying its Complementary product ranges. Essential Products sales reached €334.5 million, growing 4.1% at constant exchange rates, driven by a strong fourth quarter increase of 8.0%. The company completed transferring manufacturing of its parasiticide range to its own facilities. Essential Products now represent 64% of total sales, up from 61% in 2024. Companion animal products accounted for 72% of sales at €377 million, whilst farm animal products represented 28% at €149 million.

dvm360
Jan 28th, 2022
Vetoquinol SA launches fluorescent light therapy system for dogs and cats—Phovia

Vetoquinol released the first fluorescent light therapy system for dogs and cats—Phovia—to help accelerate natural skin regeneration.

Yahoo Finance
Jan 20th, 2022
Mongeau left Nikon Optical Usa, Inc. as CEO for Canada and the USA on Dec 20th 21'.

Mongeau joins Vetoquinol from Nikon Optical, where she most recently served as CEO for Canada and the USA.

Recently Posted Jobs

Sign up to get curated job recommendations

Vetoquinol is Hiring for 17 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →